Ads
related to: zydus pharmaceuticals generics
Search results
Results From The WOW.Com Content Network
Zydus Lifesciences Limited, formerly known as Cadila Healthcare Limited, [3] is an Indian multinational pharmaceutical company headquartered in Ahmedabad, which is primarily engaged in the manufacturing of generic drugs. [4] [5] [6] The company ranked 100th in the Fortune India 500 list in 2020. [7]
Zydus Lifesciences and Sun Pharmaceuticals have entered an agreement in October 2023 to co-market Desidustat. Sun Pharma will sell the drug as Rytstat, while Zydus will continue to sell it as Oxemia. [6]
India's Zydus Lifesciences is aiming to launch its first new drug in the United States by early 2026, looking to tap into the multi-billion dollar market for treating a type of liver disease ...
Cadila Pharmaceuticals is an Indian multinational pharmaceutical company based in Ahmedabad. The company's operations focus on manufacturing products ranging from active pharmaceutical intermediates , finished formulations , food supplements, biotechnology products and pharmaceutical machinery.
Teva Pharmaceutical Industries Ltd. (also known as Teva Pharmaceuticals) is an Israeli multinational pharmaceutical company. Teva specializes primarily in generic drugs , but other business interests include branded-drugs, active pharmaceutical ingredients (APIs) and, to a lesser extent, contract manufacturing services and an out-licensing ...
Zydis technology was developed by R.P. Scherer Corporation (currently owned by Catalent Pharma Solutions) in 1986. [2] The technology's first commercial application was in August, 1993, when a new dosage form of Pepcidine from Merck & Co. was launched in Sweden.
Gujarat has become a hub for the pharmaceutical industry, with several established companies such as Torrent Pharmaceuticals, Zydus Lifesciences, Cadila Pharmaceuticals, Alembic Pharmaceuticals, Sun Pharma, Claris, Intas Pharmaceuticals, and Dishman Pharmaceuticals having operations in the state.
They formed an alliance with German biotech firm Pieris Pharmaceuticals for developing and marketing a new class of protein therapeutics. [13] Zydus was the first to file to sell a generic version of Shire PLC's $1.1 billion ulcer drug, Lialda, in the U.S and the FDA had awarded it six months of exclusivity. [14]